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NeurodegenerationFriedreich's ataxia (FA) is a recessive, predominantly neurodegenerative disorder caused inmost cases by muta-
tions in the ﬁrst intron of the frataxin (FXN) gene. This mutation drives the expansion of a homozygous GAA re-
peat that results in decreased levels of FXN transcription and frataxin protein. Frataxin (Fxn) is a ubiquitous
mitochondrial protein involved in iron–sulfur cluster biogenesis, and a decrease in the levels of this protein is re-
sponsible for the symptoms observed in the disease. Although the pathological manifestations of FA are mainly
observed in neurons of both the central and peripheral nervous system, it is not clear if changes in non-
neuronal cells may also contribute to the pathogenesis of FA, as recently suggested for other neurodegenerative
disorders. Therefore, the aims of this study were to generate and characterize a cell model of Fxn deﬁciency in
human astrocytes (HAs) and to evaluate the possible involvement of non-cell autonomous processes in FA. To
knockdown frataxin in vitro, we transduced HAs with a speciﬁc shRNA lentivirus (shRNA37), which produced
a decrease in both frataxin mRNA and protein expression, along with mitochondrial superoxide production,
and signs of p53-mediated cell cycle arrest and apoptotic cell death. To test for non-cell autonomous interactions
we culturedwild-typemouseneurons in thepresence of frataxin-deﬁcient astrocyte conditionedmedium,which
provoked a delay in the maturation of these neurons, a decrease in neurite length and enhanced cell death. Our
ﬁndings conﬁrm a detrimental effect of frataxin silencing, not only for astrocytes, but also for neuron–glia inter-
actions, underlining the need to take into account the role of non-cell autonomous processes in FA.
© 2014 Elsevier Inc. All rights reserved.Introduction
Friedreich's ataxia (FA) is a hereditary disorder caused inmost cases
by the expansion of GAA repeats in the ﬁrst intron of the frataxin (FXN)
gene, which dampens the expression of frataxin (Fxn), a protein
involved in the biogenesis of iron–sulfur clusters and the regulation of
oxidative stress (Campuzano et al., 1996; Campuzano et al., 1997;
Pastore and Puccio, 2013). FA is characterized by progressive neurode-
generation that mainly affects the dorsal root ganglia, the corticospinal
and spinocerebellar tracts of the spinal cord, and the deep cerebellar
nuclei (Delatycki and Corben, 2012; Koeppen and Mazurkiewicz, 2013).
Until recently, neurodegenerative diseases have been regarded as exclu-
sively neuronal disorders and the contributionof non-neuronal cells to FA
has been largely ignored. However, there is now considerable evidence
that the selective death of certain types of neurons is not only due toAs, human astrocytes; shRNA,
cular Severo Ochoa (CBMSO),
co, C/Nicolás Cabrera 1, 28049
.
ect.com).intrinsic changes within the vulnerable neurons but also, to additional
changes within neighboring non-neuronal glial cells (Verkhratsky et al.,
2012). Indeed, non-cell autonomous mechanisms mediated by glial dys-
function appear to contribute to the vulnerability of neurons in many
neurodegenerative diseases (Liu et al., 2005; Ilieva et al., 2009; Lu et al.,
2009; Rodriguez and Verkhratsky, 2011; Tao et al., 2011; Di Malta et al.,
2012; Garden and La Spada, 2012; Meyer et al., 2014). In the case of FA,
speciﬁc silencing of Fxn in glial cells triggers a phenotype in Drosophila
similar to that observed after ubiquitous Fxn reduction, characterized
by altered lipid metabolism in glial cells, degeneration of neurons,
severely impaired locomotor activity and reduced lifespan (Navarro
et al., 2010). Thus, it seems plausible that non-cell autonomous processes
might contribute to neurodegeneration in FA.
Astrocytes are the most abundant glial cell type in the central ner-
vous system (CNS), and fulﬁll a wide variety of complex and essential
functions responsible for maintaining brain homeostasis (Barres,
2008; Belanger et al., 2011), such as: controlling ﬂuid movement be-
tween the intracellular and extracellular space; protecting neurons
against oxidative stress; regulating energy metabolism and blood
ﬂow; and modulating neuronal activity through the expression of cyto-
kines, growth factors and transporters (Sofroniew and Vinters, 2010;
Allaman et al., 2011). These cells are crucial for the correct functioning
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less, while the functional effects of Fxn depletion in neurons have been
studied to some extent (Palomo et al., 2011; Mincheva-Tasheva et al.,
2014), less is known about the consequences of Fxn loss in astrocytes.
Using an in vitro approach, we have characterized the effects of Fxn
depletion in cultured human astrocytes (HAs). Accordingly, we describe
the detrimental effects of Fxn deﬁciency in astrocytes, and we provide
evidence that this astrocyte dysfunction has a negative impact on neu-
ronal maturation and survival. Therefore, our results provide evidence
of the crucial contribution of non-cell autonomous glial interactions in
the neurodegeneration observed in FA.
Materials and methods
Lentiviral production and titration
To establish an in vitro model of Fxn knockdown in human
astrocytes, lentiviral vectors expressing short hairpin RNA (shRNA)
sequences were purchased from Sigma-Aldrich (Madrid, Spain)
and they contained either the sequences against the human FXN
gene (shRNA37: Mission® shRNA, Gene Bank accession number
NM_000144), or a non-speciﬁc scrambled control (SCR: Mission®
Non-Target shRNA, SHC002). Lentiviral packaging, stock production
and titration was performed as described previously (Follenzi and
Naldini, 2002).
Cell cultures
Human astrocyte cultures
Primary human astrocytes (HAs: generously donated by Dr. Vega
García-Escudero and Dr. Filip Lim, Centro de Biología Molecular Severo
Ochoa, Madrid, Spain) were obtained from ScienCell Research Laborato-
ries (Cat no 1800; Carlsbad, CA, USA). The cells were cultured in astrocyte
medium (Sciencell Cat no 1801) in 2 μg/cm2 poly-L-lysine-coated (PLL:
Sigma-Aldrich) 100 mm culture dishes and handled according to the
manufacturer's recommendations. Before any experimentation started,
the HAs were characterized by immunostaining for two well-known as-
trocyte markers: rabbit anti-GFAP (1:500; Promega Biotech, Madrid,
Spain) and mouse anti-S100β (1:1000; Sigma-Aldrich). Conﬂuent cells
were detached in 0.25% Trypsin/0.5 mM ethylenediaminetetraacetic
acid (EDTA), and they were seeded in 60 mm dishes or in multi-well
plates (with or without glass coverslips) at a density between 5000 and
7500 cells/cm2. The cells were left in medium for at least 2 days in vitro
(DIV) and then transduced with the lentiviral vectors or left as controls.
Astrocyte conditioned medium (ACM)
Conditionedmedium fromHAswas prepared as describedpreviously,
with somemodiﬁcations (Lafon-Cazal et al., 2003). Equal number of cells
were plated in astrocyte medium and transduced with SCR or shRNA37
lentiviral vectors. After 48 h, the medium was replaced with neuronal
medium and after a further 48 h, ACM was collected at 96 h post trans-
duction. Upon collection, the ACM was centrifuged twice to eliminate
cell debris, ﬁltered and frozen at−20 °C.
Primary neuronal cultures
Primary cortical neurons were prepared from C57BL/6 mice
(embryonic days 16–18), as described previously (Tapia et al., 2010).
Brieﬂy, pregnantmicewere sacriﬁced by cervical dislocation, the fetuses
were removed and decapitated, and the meninges were stripped off
the exposed brain. The cortices were removed and digested in
trypsin (0.25%: Life Technologies, Madrid, Spain) containing DNaseI
(1 mg/ml: Roche Diagnostics, Madrid, Spain) for 15 min at 37 °C,
and then dissociated by trituration with a ﬁre-polished Pasteur
pipette. The dissociated cortical cells were plated in multiwell
dishes previously coated with PLL (1 mg/mL) or on PLL-coated cov-
erslips, and maintained in Neurobasal® medium (Life Technologies)supplemented with 10% horse serum at densities ranging from 40,000
to 60,000 cells/cm2. To analyze the possible effects of conditioned
medium from Fxn-depleted astrocytes on neuronal growth and
maturation, the medium was changed after 3 h to either neuronal
medium (Neurobasal medium supplemented with B-27® [Life
Technologies], Glutamax™ [Life Technologies] and penicillin/strep-
tomycin) or to ACM. The cells were then incubated at 37 °C in a hu-
midiﬁed atmosphere containing 5% CO2.Cell viability
Cell viability was quantiﬁed by measuring calcein acetoxymethyl
ester/propidium iodide (calcein/PI) uptake (Mattson et al., 1995). In liv-
ing cells, the non-ﬂuorescent calcein is converted to a green-ﬂuorescent
calcein after acetoxymethyl ester hydrolysis by intracellular esterases,
while non-viable cells can be distinguished by a bright red ﬂuorescence
emitted when PI intercalates into double-stranded nucleic acid in cells
with a disrupted plasma membranes. Brieﬂy, cells were incubated
at 37 °C for 20 min with 1 μM of Calcein AM (Molecular Probes, Life
Technologies) and 4 μM of PI (Sigma-Aldrich), and they were then
visualized on an Axiovert 200 ﬂuorescence inverted microscope
(Zeiss). Three randomly selected ﬁelds were captured and analyzed
per experimental condition, and the experiments were performed in
duplicate on three independent cultures. Cell viability was calculated
as the percentage of green cells relative to the total number of cells
(both red and green).Protein extraction and western blots
Following treatment, the cells were rinsed once with phosphate
buffer saline (PBS) and homogenized in lysis buffer: 20 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), 100 mM
sodium chloride (NaCl), 100 mM sodium ﬂuoride (NaF), 1% Triton
X-100, 1 mM sodium orthovanadate (Na3VO4), 5 mM EDTA and
the COMPLETE™ protease inhibitor cocktail (Roche Diagnostics). The
resulting soluble fractions were centrifuged at 16,000 ×g for 10 min at
4 °C, and the supernatants were taken as the whole cell lysate, mixed
with electrophoresis buffer and boiled for 5min. The protein concentra-
tion wasmeasured using the Bio-Rad DC protein assay, according to the
manufacturer's instructions (Bio-Rad Laboratories, Madrid, Spain). For
western blots, equal amounts of protein (10–30 μg/well) were separated
on 6–15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
gels (SDS–PAGE) and immobilized on nitrocellulose membranes (GE
Healthcare, Barcelona, Spain), following standard procedures. Themem-
branes were probed overnight at 4 °C with primary antibodies diluted in
a blocking solution (PBS containing 0.1% Tween-20 and 5% non-fat dried
milk). The membranes were then washed and exposed for 1 h at room
temperature to the appropriate secondary peroxidase-conjugated anti-
body (1:5000), visualizing the speciﬁc protein bands by chemilumines-
cence. Following detection, the membranes were stripped of antibodies
using a commercial kit (Restore Western Blot Stripping Buffer; Fischer
Scientiﬁc, Madrid, Spain) and then re-probed for other proteins. The pri-
mary antibodies used in this study were: rabbit anti-Frataxin (1:1000;
clone H155; Santa Cruz Biotechnology, Heidelberg, Germany), goat
anti-cyclin-dependent kinase inhibitor 1A; p21 (1:1000; Santa Cruz Bio-
technology), mouse anti-p53 (1:1000; DO-7; BD Biosciences, Madrid,
Spain), rabbit anti-Caspase-3 (1:500; #9662; Cell Signaling, Boston,
MA, USA). The western blots were quantiﬁed by densitometry using
NIH ImageJ (Bethesda, MD, USA) open source software and the absolute
values (arbitrary units) from each experimental group were normalized
to those obtained for mouse anti-β-actin (1:5000; Sigma-Aldrich) used
as a control for loading. The results are presented in arbitrary units
expressed as the change relative to their respective controls that were
run simultaneously.
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The superoxide anions within mitochondria were measured by
ﬂow cytometry with the MitoSOX™ Red probe (Molecular Probes, Life
Technologies) following a previously described protocol (Mukhopadhyay
et al., 2007). The astrocytemediumwas removed from the culture plates
96 h after shRNA37 transduction and it was replaced with medium
containing 5 μMMitoSOX™ Red, in which the cells were incubated for
30 min. While minimizing their exposure to light, the cells were recov-
ered by trypsinization and centrifuged at 1000 rpm for 5 min. The pel-
lets were washed twice with Hank's balanced salt solution (HBSS; Life
Technologies) and re-suspended in 500 μl of Mitochondria Incubation
Buffer (MIB: 68mM sucrose, 10 mMHEPES [pH 7.4], 70 mM potassium
chloride [KCl], 1 mM ethylene glycol tetraacetic acid [EGTA]: all from
Sigma-Aldrich). As a positive control, 10 μM of the apoptosis-inducing
agent Antimycin A (Sigma-Aldrich)was added to the cells. Subsequently,
the cell suspensionswere transferred to cytometry tubes and analyzed in
a FACSCanto II ﬂow cytometer (BD Biosciences) with 488 nm excitation,
measuring MitoSOX™ red in the FL2/3 channels and collecting at least
≥15,000 events per condition. To measure oxidized MitoSOX in HAs
data were collected and plotted for forward (FSC) vs side (SSC) scatter
to exclude the artifactual oxidation of necrotic cells to the overall oxida-
tion measurements. The results were examined using the FlowJo soft-
ware by plotting each population as a histogram of mean intensity
(FL2). Experiments were performed in triplicate and the data represent
the geometric mean ± S.E.M. of three independent experiments.
Human antibody-based protein arrays of astrocyte conditioned medium
Equivalent numbers of human astrocytes were cultured in complete
astrocyte medium and transduced with SCR or shRNA37 lentiviral
vectors. The medium was changed to serum-free astrocyte medium
48 h after transduction and collected after a further 48 h. The secretome
of HAswas analyzedwith the RayBio®Human Cytokine Antibody Array
C series 1000 kit (RayBiotech, Inc., Norcross, GA, USA) according to the
manufacturer's instructions. The assay membranes can detect 120 dif-
ferent growth factors and cytokines at a time. Brieﬂy, each membrane
was placed into the 8-well tray provided, and it was incubated at
room temperature in 2 mL of the blocking buffer provided for 30 min.
The blocking buffer was decanted and the membranes were incubated
overnight with 1 mL of media from SCR or Fxn-depleted human astro-
cytes at 4 °C. After removing the media, the containers were washed 3
times with 2 mL of wash buffer I at room temperature with shaking
for 5 min and they were then washed twice more with 2 mL of wash
buffer II at room temperature with shaking for 5 min. The membranes
were probed overnight at 4 °C with 1 mL of diluted primary biotin-
conjugated antibody, and after washing with wash buffer I and II, anti-
body binding to the membranes was detected by incubation with
2mLof 1000-fold dilutedHRP-conjugated streptavidin at room temper-
ature for 2 h. The membranes were again washed twice and placed into
the visualization buffer. Excess visualization reagent was drained off
and themembraneswere coveredwith a cleanpiece of plastic. Antibody
binding was visualized by chemiluminescence in an ImageQuant™ LAS
4000mini imaging system (GEHealthcare) and the spots detectedwere
quantiﬁed by the apparatus. After blank subtraction, the data were
normalized to the positive controls provided by the manufacturer and
the results are expressed asmean fold change±S.E.M. of SCR condition.
Sample collection and RNA extraction
After treatment, the cells were washed once with PBS, frozen on dry
ice and stored at−80 °C. For reverse transcription-polymerase chain re-
action (RT-PCR), total RNA was extracted using RNeasy mini columns
(Qiagen, Hilden, Germany) and any contaminating genomic DNA was
eliminated by DNaseI (Qiagen) digestion. The yield and purity of theRNA was determined using a Nanodrop spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA).
Reverse transcription and quantitative PCR (qPCR)
Total RNA (0.5 μg in 20 μL) was reverse transcribed into cDNA
(25 ng/μl ﬁnal concentration), using the Super Script III First Strand
Synthesis SuperMix kit for qPCR (Invitrogen, Life Technologies), with a
mix of random and oligo(dT) primers. Primers (human) were designed
from previously published sequences or in house (Table 1) and to avoid
genomic DNA ampliﬁcation, the primers were designed to span intron–
exon boundaries (all from Sigma-Aldrich). For FXN, PIGF, HGF, IGFBP-3,
IL-6 and VPA genes, qPCR was performed on 2.5 ng of cDNA with the
SsoFast EvaGreen supermix (BioRad Laboratories) with 500 nMprimers
and using the CFX 384 system (BioRad Laboratories)with cycling condi-
tions of: 95 °C for 5 s; 40 cycles of 95 °C for 5 s+ 60 °C for 5 s; and 60 °C
for 5 s + 95 °C for 5 s. In the case of MIP-1α, qPCR was performed from
25 ng of cDNA using the Power SYBR Green PCR Master Mix (Applied
Biosystems, Life Technologies) with 250 nM primers and using the
7900HT Fast system (Applied Biosystems, Life Technologies) with
cycling conditions of: 95 °C for 10 s; 40 cycles of 95 °C for
15 s + 60 °C for 60 s; and 95 °C for 15 s + 60 °C for 15 s + 95 °C for
15 s. To ensure the absence of possible genomic DNA contamination,
we used the ValidPrime method (Laurell et al., 2012), measuring the
genomic DNA content in RT(+) samples with commercially available
reference samples and primers (ValidPrime™, TATAA Biocenter,
Sweden). The data were analyzed and corrected (where necessary)
with the GenEx software. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression was used to normalize the data and to obtain rel-
ative expression values with the comparative Ct method. The results
are expressed as the fold-change compared to SCR HAs ± S.E.M. of
three independent cultures measured in triplicate.
Immunocytochemistry and optical/confocal microscopy
Immunostaining of cellswasperformed followingour previously de-
scribed procedures (Loria et al., 2010). Cells plated on PLL-coated cover-
slips were ﬁxed in 4% paraformaldehyde for 10 min and non-speciﬁc
binding was blocked with 2% bovine serum albumin (Sigma-Aldrich)
in PBS containing 0.1% TritonX-100. The cellswere then incubated over-
night at 4 °C with the primary antibodies mouse anti-SMI31 (1:1000;
Covance, Princeton, NY, USA) and rabbit polyclonal anti-microtubule-
associated protein 2 (1:1000, 514) (Sanchez Martin et al., 1998). After
rinsing with PBS, antibody binding was detected with Alexa Fluor 488
(1:1000, goat anti-mouse IgG; Molecular Probes, Life Technologies) or
Alexa Fluor 555 (1:1000, goat anti-mouse IgG; Molecular Probes, Life
Technologies) secondary antibodies for 1 h at room temperature. The
nuclei were counterstained with DAPI (1:5000; Calbiochem, Millipore,
Madrid, Spain) and after washing, the glass coverslips were mounted
on slides. Non-speciﬁc interactions of secondary antibodies were
veriﬁed by omitting the primary antibodies. To visualize intact mito-
chondria and mitochondrial superoxide production, live cells were
labeled with MitoTracker red and MitoSOX red probes, according to
the manufacturer's instructions. After ﬁxation and immunostaining,
images were acquired either with an LSM710 vertical laser scanning
confocal microscope (Zeiss) or with an Axiovert 200 ﬂuorescence
inverted microscope coupled to a CCD camera (Zeiss).
Neuronal quantitative analysis
To analyze neurite outgrowth and branching in primary neuronal
cultures, after immunostaining with SMI31 or MAP-2, the cells were
observed on a Zeiss Axiovert 200 inverted ﬂuorescence microscope
equipped with a CCD camera. For each experimental condition, at
least ﬁve randomly chosen ﬁelds were captured and the axons and den-
drites were traced from the cell body to the end of their prolongations,
Table 1
Primers used for SYBR Green qPCR.
Protein/gene name Accesion no. Primer name Sequence (5′–3′)
Frataxin (FXN) NM_000144 FXN-Fw TGGAATGTCAAAAAGCAGAGTG
FXN-Rv CCACTCCCAAAGGAGACATC
Phosphatidylinositol glycan anchor biosynthesis (PIGF) NM_002643.3 PIGF-Fw TAGGACCAAACCTCAAAGCA
PIGF-Rv AAAGACCATGGCAGGTATGG
Hepatocyte growth factor (HGF) NM_000601.4 HGF-Fw TCGGGGTAAAGACCTACAGGA
HGF-Rw AATGGGGAGAGTTATCGAGGT
Insulin-like growth factor binding protein 3 (IGFBP-3) NM_001013398 IGFBP3-Fw GCCAGGAAATGCTAGTGAGTCG
IGFBP3-Rv GGCAGGGACCATATTCTGTCT
Interleukin 6 (IL-6) NM_000600.3 IL-6-Fw CACTCACCTCTTCAGAACG
IL-6-Rv ATTTGTGGTTGGGTCAGGG
Macrophage inﬂammatory protein 1 alpha (MIP-1α) NM_002983 MIP-1α-Fw CAACCAGTTCTCTGCATCACTTG
MIP-1α-Rv GCCGGGAGGTGTAGCTGAA
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) NM_002046.4 GAPDH-Fw CCCCTGGCCAAGGTCATCCATG
GAPDH-Rv CAGTGAGCTTCCCGTTCAGCTC
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NeuronJ (Meijering et al., 2004). In the case of neuron number, the
total DAPI positive cells were counted in each ﬁeld and condition. For
all measurements, the results were normalized to the CTL condition
and they are presented as the mean percentage ± S.E.M.
Statistics
Statistical analysis was performed using the SPSS 18.0 statistical
package. The results are expressed as the mean ± standard error
mean (S.E.M.). Unless stated in the ﬁgure legend, the Student's t-test
was used to compare between two groups. If the Levene's test for homo-
geneity of variances was signiﬁcant then the Mann–Whitney's U non-
parametric test was used. Statistical signiﬁcance was attributed when
p ≤ 0.05.
Results
Reduced in vitro expression of frataxin in glial cells after shRNA-mediated
knockdown
In order to determine and characterize the effects of Fxn deﬁciency
in glial cells, and since the use of lentiviral vectors has proven to be a
useful tool to study biological mechanisms (Aurelie et al., 2013), weFig. 1. Frataxinprotein andmRNAexpression inHAs after in vitro knockdown. (A)HAswere cult
times indicated. The cells were lysed and recovered, and equal amounts of protein from these c
(as a loading control). The lower panel shows the quantiﬁcation of the CTL (light gray bar), SCR
were compared with CTL and SCR cells at 96 h. (B) Total mRNAwas extracted from HAs 96 h af
expressionwas analyzed by qPCR. FXN expression was normalized to GAPDH and the histogram
and ***p b 0.001 compared to SCR.established an in vitro model of Fxn knockdown through a Fxn-speciﬁc
shRNA (shRNA37) lentiviral vector. First, we investigated the Fxn protein
in HAs at different time points up to 96 h after the transduction of the
shRNA37 vector and compared Fxn levels with those of untransduced
cells (CTL) and scrambled (SCR) transduced cells at 96 h. In western
blots we observed a progressive decrease in Fxn levels from 24 h post-
transduction that continued falling until 96 h post-transduction when
the protein levels reached approximately 24% of the control cells
(Fig. 1A). Since the majority of FA patients have Fxn protein levels be-
tween 10% and 25% of normal values and our data indicated that similar
levels were achieved after 96 h of transduction, we assessed the Fxn
mRNA in astrocytes at this time point after shRNA37 or SCR transduction
by quantitative PCR (qPCR). Fxn mRNA expression was signiﬁcantly
downregulated in Fxn-deﬁcient HAs compared with the SCR transduced
controls, with almost undetectable Fxn expression in those cells
(Fig. 1B). Together these data conﬁrmed that both Fxn protein and
mRNA is diminished in our in vitro HA model of Fxn knockdown.
Mitochondrial superoxide production after frataxin silencing in human
astrocytes
The negative effects of Fxn deﬁciency, speciﬁcally in the mitochon-
dria, are related to the cell's redox status (Lefevre et al., 2012;
Gonzalez-Cabo and Palau, 2013). Therefore, 96 h after transductionuredunder standard conditions (CTL) or transducedwith SCRor shRNA37 lentivirus for the
ells (15 μg/lane) were immunoblotted and probedwith antibodies against Fxn and β-actin
(dark gray bar) and shRNA37-transduced (black bar) signals fromHAs. All the time points
ter transduction with SCR (dark gray bar) or shRNA37 (black bar) lentivirus and FXN gene
s show themean values± S.E.M. from at least three independent experiments: **p b 0.01
Fig. 2.Morphological changes in mitochondria and superoxide production in Fxn-depleted HAs. (A) Representative confocal photomicrographs of CTL, SCR or shRNA37-transduced HAs
stained with the MitoTracker red probe. The nuclei were counterstained with DAPI (blue). (B) Fluorescence microscopy images showing representative staining of CTL, SCR or shRNA37
astrocytes after immunostaining with the MitoSOX red probe and DAPI (blue). Scale bar in (A) and (B); 50 μm. (C) Increased mitochondrial superoxide production in live astrocytes
assessedwith theMitoSOX red probe and by ﬂowcytometry. The panel summarizes theﬂowcytometry data from three independent experiments. The bar graph represents the geometric
mean ± S.E.M. (arbitrary units) of the MitoSOX ﬂuorescence intensities of CTL (light gray bar), SCR (dark gray bar) and shRNA37-transduced HAs (black bar). Results in (A), (B) and
(C) correspond to data analyzed at 96 h in all experimental conditions: **p b 0.01 compared with SCR.
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morphology and superoxide generation in HAs labeled with MitoTracker
red and MitoSOX red probes. In terms of mitochondrial integrity evident
by confocal microscopy, the typical ﬁlamentous mitochondria character-
istic of control cells were replaced by severely swollen mitochondria and
punctate MitoTracker staining in Fxn-deﬁcient astrocytes (Fig. 2A). Fur-
thermore, the weak MitoSOX ﬂuorescence in control conditions became
a strong signal in the cells lacking Fxn, reﬂecting superoxide formation
(Fig. 2B). Thus, we evaluated the mitochondrial oxidant burden in live
Fxn-deﬁcient astrocytes tagged with the MitoSOX red probe 96 h after
lentiviral vector transduction. Flow cytometry analysis showed that
Fxn-deﬁcient cells produce more superoxide than either control or SCR
astrocytes measured also at 96 h (Fig. 2C), reﬂected by signiﬁcantly
more intense red MitoSOX ﬂuorescence.
Frataxin knockdown decreases the viability and proliferation of human
astrocytes
Having established our in vitromodel of Fxn knockdown in human
astrocytes, we studied whether lower levels of Fxn affected the rate of
cell survival. Astrocyte viability, was measured over 96 h, evaluating cellviability every 24 h as the percentage of calcein positive cells relative to
the total cell number (Fig. 3A).While no change in this parameterwas ob-
served between24 and48h, shRNA37 transduction decreasedHA surviv-
al to 80% at 72 h post-transduction and to 69% after 96 h (Fig. 3B). To
discern if Fxn depletion induced changes in cell proliferation in addition
to cell death, we tracked the total cell number (calcein/PI positive cells)
over time and we found a signiﬁcant reduction of the total number of
cells 48, 72 and 96 h after Fxn knockdown but not in the control HAs or
SCR transduced cells, the numbers of which increased progressively
(Fig. 3C). This suggests that in our model, an acute decrease in Fxn levels
slows down cell proliferation and induces the death of HAs.
Signs of possible cell cycle arrest and apoptosis in human astrocytes after
frataxin silencing
The transcription factor p53 plays a key role in regulating events like
DNA repair and the cell cycle (Jebelli et al., 2012). Moreover, p53 is in-
volved in the induction of apoptosis, particularly in a neuronal model
of Fxn silencing (Palomo et al., 2011). Accordingly, we hypothesized
that this protein could be involved in the cell death associated with
the decreased cell proliferation and viability of HAs when Fxn was
Fig. 3. Fxn knockdown in HAs decreases cell survival and proliferation. (A) Cell viability was estimated by calcein/PI uptake. Live CTL HAs or those transduced with SCR or shRNA37were
incubatedwith amixture of both dyes and visualized byﬂuorescencemicroscopy at the times indicated. Representative images of the live (calcein positive, green) and dead/dying cells (PI
positive, red). Scale bar: 100 μm. (B) The number of live astrocytes (green) was quantiﬁed with respect to the total cell number (green + red), and expressed as a percentage of the CTL
cells at each time point. (C) Quantitative analysis of cell proliferation estimated through the total cell number in each condition over 4 DIV. The data represent themean± S.E.M. of at least
6 images per condition from three independent experiments: *p b 0.05 and ***p b 0.001 comparedwith SCR condition. In (B) and (C): CTL, light gray bar; SCR, dark graybar; shRNA37, black
bar.
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Fxn-depleted HAs in western blots, and we found signiﬁcantly more
p53 in astrocytes lacking Fxn at all time points evaluated (Figs. 4A and
D).We alsomeasured the expression of the cyclin-dependent kinase in-
hibitor 1A (p21), a downstream effector of p53-mediated cell cycle ar-
rest. As expected, from 48 h after shRNA37 transduction we detected a
sustained increase of p21 expression in these cells (Figs. 4B and D). Fi-
nally, we determined whether there was any change in the well-
known marker of apoptotic events, caspase-3. The lack of Fxn induced
a time dependent increase in cleaved caspase-3 compared with both
the control and SCR groups (Figs. 4C and D). For the 3 proteins evaluat-
ed, the time points were comparedwith control levels corresponding to
untransduced and SCR cells collected at 96 h. These results suggest that
a deﬁciency of Fxn in HAs triggers the activity of p53, p21 and caspase-3
(cleaved), implying that the cell death of these cells may be at least in
part due to apoptosis and the activation of the p53 pathway.
Cytokine proﬁling of conditioned medium after frataxin silencing in
human astrocytes
Given the role of glial cells in fundamental processeswithin the CNS,
characterizing the secretome of these cells under homeostatic and
pathological conditions is becoming ever more relevant (Dowling andClynes, 2011). To examine the functional consequences of Fxn silencing
in HAs in more detail, we analyzed the secretome of these cells by
collecting serum-free astrocyte conditioned medium (ACM) after 48 h
of conditioning (a total of 96 h after SCR or shRNA37 lentiviral transduc-
tion). Using an array that identiﬁes up to 120 cytokines (Fig. 5A), we
detected 49 cytokines with increased secretion (mild to strong), and 6
cytokines with decreased secretion in Fxn-depleted HAs (data not
shown, see Fig. 5B for the most relevant ﬁndings). According to their
principal functions, these cytokines were classiﬁed into the following
groups: i) proliferation/angiogenesis; ii) immunity/inﬂammation;
iii) growth factors/growth factor receptors; and iv), broad-acting cyto-
kines (Table 2). These cytokine array results were validated at the
transcriptional level by qPCR (Fig. 5C) and we detected signiﬁcant
increases in the mRNA expression of HGF, IGFBP-3, IL-6, PIGF and
MIP-1α, with no obvious changes in GRO-α, MIF or GFBP-2 expres-
sion. For some of the genes analyzed (e.g. Angiogenin, ICAM-3 or
VEGF-α), the transcriptional changes detected by qPCR were not
consistent with the cytokine array data, which may reﬂect the inﬂu-
ence of other post-transcriptional regulatory events (data not
shown). Nevertheless, the consistent increase in the mRNA expres-
sion and secretion of HGF, IGFBP-3, IL-6, PIGF and MIP-1α provoked
by Fxn-deﬁciency suggests a functionally relevant alteration in cell
communication pathways.
Fig. 4. Increased expression of cell cycle and apoptosis-related proteins after Fxn shRNA silencing in glial cells. Representative immunoblots of the tumor suppressor protein p53 (A), its
downstream effector p21 (B), and themarker of apoptosis, cleaved caspase-3 (C). Equal amounts of protein (15–30 μg) from CTL and SCR cells collected at 96 h, and fromHAs at different
time points after shRNA37 transduction were resolved by SDS-PAGE (15%), immunoblotted and probed with the corresponding antibody. In all cases, β-actin was used as a loading
control. (D) Quantiﬁcation of (A–C), where the data represent the mean ± S.E.M. (arbitrary units) normalized to the control after densitometry of data from at least three independent
experiments: *p b 0.05, **p b 0.01 and ***p b 0.001 compared with SCR.
Fig. 5.Cytokine release in Fxn-deﬁcient humanastrocyte conditionedmedium (ACM). (A) Representative antibody arrays (120 cytokines; i and ii) incubatedwith ACM(48h) from the SCR
(upper panels) and shRNA37 (lower panels) transduced cells (96 h after transduction). Rectangles indicate the positive controls (green), and some of the up-regulated (red) and down-
regulated (blue) cytokines. (B) Bar graph showing the quantiﬁcation of the cytokines released by shRNA37 transduced HAs (black bars), presented as the fold change with respect to the
SCR condition (dark gray bars). (C) Real-time PCR ampliﬁcation of the HGF, IGFBP-3, IL-6, PIGF andMIP-1α transcripts in SCR (dark gray bars) or Fxn-depleted HAs (black bars) measured
96 h post-transduction. ThemRNA expression was quantiﬁed by the comparative Ctmethod and the data are presented as themean fold change± S.E.M. from at least three independent
samples per experimental condition: *p b 0.05 and ***p b 0.001 compared with SCR.
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Table 2
Proﬁle of cytokine release from Fxn-depleted ACM.
Cytokines Fold increase/decrease
Angiogenesis/proliferation
Tissue inhibitor of metalloproteinases (TIMP‐1) 2.45
Vascular endothelial growth factor A (VEGF-A) 1.93
Angiogenin (ANG) 2.09
Phosphatidylinositol glycan anchor biosynthesis (PIGF) 1.40
Immunity/inﬂammatory
Intercellular adhesion molecule 1 (ICAM-1) 1.66
Monocyte Chemotactic Protein 2 (MCP-2) −1.53
Macrophage migration inhibitory factor (MIF) 2.54
Intercellular adhesion molecule 3 (ICAM-3) 1.64
Growth regulated oncogene-alpha (GRO-α) 2.11
Macrophage inﬂammatory protein 1 alpha (MIP-1α) 1.72
Chemokine (C–C motif) ligand 16 (HCC-4) 2.14
Broad-acting cytokines
Interleukin 6 (IL-6) 1.68
Growth factors/binding proteins
Hepatocyte growth factor (HGF) 4.81
Insulin-like growth factor binding protein 2 (IGFBP-2) 1.64
Insulin-like growth factor binding protein 3 (IGFBP-3) 1.57
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development and survival of mouse neurons
One of the main functions of astrocytes is to maintain a healthy
environment for neurons by releasing factors that support their growth,
development and survival (Sofroniew, 2013). However, they may have
a beneﬁcial or detrimental inﬂuence on neuronal survival in function
of the context (Zamanian et al., 2012; Verkhratsky et al., 2013). To ex-
amine the possible functional effects of Fxn depletion in HAs on
astrocyte–neuron interactions, we cultured wild-type mouse cortical
neurons in the presence of ACM from CTL, SCR or Fxn-deﬁcient HAs
(the ACM and wild-type cortical mouse neurons from E17 embryos
were prepared as indicated in the Materials and methods section).
The plating medium was shifted to ACM 3 h after seeding and the
cells were then maintained under these conditions for up to 3 DIV
(Fig. 6A), when neurite outgrowth was analyzed by immunocytochem-
istry with SMI31/MAP-2 and cell viability was quantiﬁed by calcein/PI
capture and nuclei counts. Subsequent confocal microscopy analysis of
SMI31 positive cells revealed that the axons of wild-type neurons
grown in CTL-ACM or SCR-ACM lengthened at a normal rate and that
the density of the neurons was normal. By contrast, the addition of
shRNA37-ACM induced a signiﬁcant decrease (slightly more than
50%) in axonal branching and neuronal density (Figs. 6B and E). In
terms of cell survival, while no signiﬁcant differences were detected
after 2 DIV, the survival of cortical neurons signiﬁcantly decreased to ap-
proximately 60% the control values in the presence of shRNA37-ACM
after 3 DIV (Fig. 6C), as conﬁrmed by the total number of DAPI positive
cells detected after 3 days in the presence of shRNA37-ACM (Fig. 6D). In
addition, we also found that shRNA37-ACM signiﬁcantly reduced the
dendritic arborization of neurons (measured by MAP-2 staining) to ap-
proximately 50% that of neurons exposed to CTL and SCR ACM (Fig. 6F).
Since these effects occur without any direct contact between astrocytes
and neurons, our results suggest that the morphological changes and
neuronal death triggered by the ACM from cells lacking Fxn is mediated
by one or more soluble factors released by HAs.Discussion
FA is a multisystemic disease caused by reduced levels of the Fxn
protein (Corben et al., 2012). Although its main clinical features involve
the degeneration of neurons in the central and peripheral nervous sys-
tem (Delatycki and Corben, 2012), little is known about the possiblecontribution of glial cells, and speciﬁcally of astrocytes, to the initiation
and propagation of this disease. Since astrocytes are themain regulators
of brain homeostasis and they have previously been implicated in the
pathogenesis of other neurological conditions (Verkhratsky et al.,
2012), it appears plausible that the loss of normal astrocyte activity
may have negative consequences on glial–neuron interactions in FA.
In this study, an in vitro model of Fxn knockdown was established
and characterized in human astrocytes. Using this approach, we were
able to reduce Fxn protein and mRNA expression to levels similar to
those observed under pathological conditions. This Fxn silencing
inhibits cell proliferation and induces death of human astrocytes,
changes that are accompanied by a signiﬁcant up-regulation of the
tumor suppression protein p53, the cell cycle regulatory protein p21
and the apoptotic marker caspase-3. We also found that as a conse-
quence of Fxn deﬁciency, the morphology of the mitochondria in
these cells is altered and they suffer greater oxidative stress. In addition,
we found that Fxn-deﬁcient astrocytes produce a variety of cytokines
and growth factors that in turn might inﬂuence their capacity to
provide trophic support to neurons. Indeed, primary mouse neurons
undergo delayed maturation and cell death when cultured in ACM
from Fxn-deﬁcient cells.
Since Fxn was ﬁrst identiﬁed, the protein was shown to be strongly
expressed in the mitochondria of neurons and astroglia (Campuzano
et al., 1997). However, there is little reference in the literature to the ex-
pression and function of Fxn in astrocytes (Kirches et al., 2011; Franco
et al., 2012). Therefore, our observation of signiﬁcantly less Fxn protein
and mRNA transcripts in human astrocytes several days after in vitro
knockdown is consistent with our data from neuron-like cells (Palomo
et al., 2011) and those from other cell types (Santos et al., 2001; Lu
and Cortopassi, 2007; Napoli et al., 2007; Zanella et al., 2008). Interest-
ingly, insulin-like growth factor 1 (IGF-1) can alter Fxn levels in mouse
astrocytes and neurons, which suggests that the intrinsic regulation of
Fxn is dependent on the cell context (Franco et al., 2012). Curiously, in
these studies mouse astrocytes appear to be much less sensitive to
Fxn deﬁciency than neurons, which would appear to contrast with our
observations of signiﬁcant cell death after frataxin depletion in HAs. It
remains to be established whether this discrepancy is due to the partic-
ular experimental conditions employed or whether it reﬂects species
differences. It is noteworthy that some signiﬁcant functional differences
have been described between mouse and human astrocytes (Oberheim
et al., 2009; Tarassishin et al., 2014), and differences in gene expression
between murine and human astrocytes might also be responsible for
their distinct susceptibility to Fxn depletion. A recent analysis of the
transcriptome of the prenatal human brain placed FXN gene within a
module enriched for genes expressed in astrocytes (Miller et al.,
2014). Clearly, further research is required to clarify this issue.
Astrocytes are considered important regulators of iron homeostasis
that become activated under pathological conditions, exerting either
beneﬁcial or detrimental effects on the surrounding environment
(Tulpule et al., 2010; Pelizzoni et al., 2013). Since Fxn is known to be
directly implicated in mitochondrial iron–sulfur cluster biogenesis, the
increase in superoxide production and the alterations to mitochondrial
morphology after Fxn depletion in astrocytes supports the idea that
increasing mitochondrial iron content favors oxidative stress within
astroglial cells. Hence, these modiﬁcations in their antioxidant defense
system might also alter neural homeostasis, an observation conﬁrmed
recently in a complex I knockdown model in Drosophila that demon-
strates the relationship between glial cells and neurotoxicity in the con-
text of mitochondrial electron transport chain disorders (Hegde et al.,
2014).
One of the main conclusions drawn after intense research into
the functions of Fxn is its involvement in early development and cell
survival. The complete deletion of Fxn in mice rapidly provokes embry-
onic lethality (Cossee et al., 2000), while FA-induced pluripotent stem
cells (iPSCs) display deﬁcient differentiation into peripheral sensory
neurons (Eigentler et al., 2013). These observations are consistent
Fig. 6. Conditionedmedium from Fxn-depletedHAs (ACM)mediates non-cell autonomous degeneration of wild-typemouse cortical neurons. (A) Scheme of the experimental design and
the time line for conditioningHAmedium.HA cultureswere transducedwith SCR, shRNA37 or left untransduced and after 48h, themediumwas replacedwith standardneuronalmedium
for conditioning over a further 48h (a total of 96 h after lentiviral transduction). (B) Representative confocal photomicrographs of normalmouse cortical neurons grown for 3 days inACM,
having labeled the axons and nuclei with anti-SMI31 (green) and DAPI (blue), respectively. Scale bar: 50 μm. (C–F) Neuron viability, total cell number and neurite length (SMI31 and
MAP-2 positive cells) were measured after 2 or 3 days in the presence of CTL-ACM (light gray bar), SCR-ACM (dark gray bar) or shRNA37-ACM (black bar). (C and D) Cell viability and
the total cell number were evaluated by the calcein/PI assay and DAPI counts. (E and F) Axonal and dendritic lengths were calculated using the NeuronJ plugin of the ImageJ software
(as described elsewhere). The data represent the mean ± S.E.M. of three independent experiments, presented as percentage of the CTL condition: ***p b 0.001 compared with SCR.
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and cell death is enhanced when Fxn levels are reduced. However, the
mechanisms by which Fxn depletion induces these alterations are not
yet fully understood. In our hands, human cortical astrocyte survival is
signiﬁcantly compromised as a consequence of the lack of Fxn, a similar
ﬁnding to that reported in rat dorsal root ganglia (Mincheva-Tasheva
et al., 2014) and in Schwann cells (Lu et al., 2009). Interestingly, we
observe a correlation between astrocyte cell death and activation of
the p53 pathway. The relationship between p53 and glial cells in a path-
ological context has beenpoorly studied until recently, and the evidence
emerging suggests a contribution of astrocytic p53 to some neurode-
generative diseases (for review see Jebelli et al., 2012). Our results sup-
port the idea that p53 is important in the response to Fxn depletion, not
only in neurons (Palomo et al., 2011) but also in glial cells. However, the
precise interaction between Fxn expression and p53 signalingmay also
depend on cell context and thus become rather complex. For instance,immortalized B lymphoblasts from FA patients exhibit increased basal
levels of phosphorylated p53 but a less efﬁcient activation of p53 upon
hypoxia (Guccini et al., 2011). This differential modulation of p53 acti-
vation by Fxn expression level in normoxia and hypoxia might also
lead to a differential recruitment of distinct p53 downstream targets
(Guccini et al., 2011). On the other hand, it has been recently described
that p53 activates the transcription of the FXN gene in a human embry-
onic kidney cell line (Shimizu et al., 2014). Further research is necessary
to clarify the complex interrelationship between Fxn and p53 in distinct
cell types under different physiopathological conditions.
Given that some important astrocyte functions are mediated by the
release of different molecules, we analyzed the secretome of human
astrocytes in our in vitro model. Astrocyte secretomes have already
been investigated in health and disease using a range of techniques
(Lafon-Cazal et al., 2003; Pocernich et al., 2005; Jha et al., 2013; Lai
et al., 2013). Our cytokine screening and validation through mRNA
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ACMof Fxn-depleted astrocytes,mainly those associatedwith processes
like immunity, inﬂammation and/or proliferation. Among the up-
regulated molecules, IL-6 has often been considered a potent pro-
inﬂammatory mediator produced by glial cells in response to various
types of insults. This up-regulation is consistent with that described
previously when Fxn is silenced in Schwann cell lines (Lu et al., 2009)
and thus, IL-6 up-regulation may represent a general glial response to
Fxn deﬁciency regulating inﬂammation. Interestingly, an increased
secretion of IL-6 has also been reported to occur after persistent DNA
damage (Rodier et al., 2009) and may be considered one of the factors
linking oxidative stress and inﬂammation. Likewise, the increased ex-
pression of the chemokineMIP-1α, which is also involved in the regula-
tion of inﬂammatory processes, is consistent with its expression in
reactive astrocytes (Murphy et al., 1995; Di Malta et al., 2012).
The up-regulation of HGF, a potent growth factor with pleiotropic
activity related to tissue protection and regeneration that is enhanced
in reactive astrocytes in vivo, is particularly relevant (Shimamura et al.,
2007; Nakamura et al., 2011; Jeong et al., 2012). Since astrocytes
exert beneﬁcial effects by regulating local immune responses, the
increased expression of this molecule by these cells when Fxn is lacking
suggests that a physiological compensatory mechanism may be trig-
gered to protect them.
The importance of studying the glial contribution to FA has been em-
phasized in a model of the disease in which the speciﬁc deletion of glial
Fxn in Drosophila generated FA-like symptoms, including a reduced
lifespan, increased sensitivity to oxidative insults and impaired locomo-
tor activity (Navarro et al., 2010). Herewe show that theACM fromFxn-
knockdown cortical astrocytes is sufﬁcient to elicit a neurodegenerative
phenotype in cortical neurons from wild-type mice, characterized by a
high rate of cell death and a reduction in neurite length. Given the al-
tered levels of some cytokines and growth factors detected in the
ACM, the release of these molecules might be at least partially
responsible for the non-cell autonomous detrimental effects observed,
although astrocytes may induce neurodegeneration in FA through
other mechanisms. Nevertheless, our results support the hypothesis
that astrocytes may become neurotoxic in FA, as proposed in other
neurological diseases. The toxic effects of astrocytes differentiated
from Rett syndrome iPSCs on the morphology and function of mouse
hippocampal neurons has recently been demonstrated in vitro, and sim-
ilar results were obtained with ACM, highlighting the non-cell autono-
mous mechanisms implicated in this neurological syndrome (Williams
et al., 2014). Along similar lines, the conditional deletion of the Dicer
endoribonuclease in astrocytes in vivo causes a wide range of neurolog-
ical alterations and premature death inmice (Tao et al., 2011), and neu-
rodegenerationwas described in an astrocyte conditionedmousemodel
of multiple sulfatase deﬁciency (Di Malta et al., 2012). Evidence of non-
cell autonomous toxicity of wild-type motor neurons was also obtained
in a co-culture systemwith neuronal progenitor cell-derived astrocytes
from patients with amyotrophic lateral sclerosis (Meyer et al., 2014).
In conjunctionwith theDrosophilamodel of glial-speciﬁc Fxn deple-
tion (Navarro et al., 2010), our cell model of Fxn deﬁciency in human as-
trocytes further suggests that non-cell-autonomous neurodegeneration
may contribute to the pathogenesis of FA. However, this work is limited
by the differences that might exist between in vitro/in vivo approaches
to study the role of astrocytes in the progression of neurodegenerative
pathologies (Cahoy et al., 2008), as well as by the heterogeneity among
astrocytes, not only in terms of morphology but also functionally,
and/or in their capacity to respond to injury (for review see Zhang and
Barres, 2010). A complementary approach would be to investigate the
possible contribution of glial cells to the initiation or progression of the
disease directly through the generation of novel conditional mouse
models of Fxn deﬁciency (Perdomini et al., 2013).
Interestingly, some recent evidence supports the hypothesis
that neuroinﬂammation may be a contributing factor to the patho-
genesis of FA (Hayashi et al., 2014). An up-regulation of induciblecyclooxygenase 2 (COX-2) and an increased biosynthesis of prostanoids
have been observed in two FAmouse models as well as in lymphocytes
from FA patients (Hayashi et al., 2014). In the discussion of their ﬁnd-
ings, Hayashi and colleagues suggest that the chronic elevation of oxida-
tive stress in FA patient cells and animal models may lead to the
secretion of cytokines responsible for COX-2 up-regulation. These au-
thors have proposed a mechanism involving Fxn-deﬁcit→ Oxidative
stress→ Cytokines→ COX-2→Neuroinﬂammation→Neurodegener-
ation (Hayashi et al., 2014). Our results agree well with this model
and emphasize the role played by astrocytes in this respect, suggest-
ing a mechanism involving Fxn-deﬁcit-in-glia→ Oxidative stress→
Cytokines→ Neuroinﬂammation→ Neurodegeneration.
Further research both in animal models and in the clinical setting is
required to investigate the role of neuroinﬂammation in the physiopa-
thology of FA. Of interest in this regard is the observation of a signiﬁcant
telomere shortening in the peripheral blood leukocytes from FA
patients compared with healthy subjects (Castaldo et al., 2013), as it
has been suggested that increased telomere attrition may be caused
by oxidative stress and inﬂammation (Eitan et al., 2014). Moreover,
the possible occurrence of demyelination in FA patients (Corben et al.,
2014) may be associated with mitochondrial dysfunction, oxidative
stress and neuroinﬂammation (Carvalho, 2013).
Astrocytes also play important roles in supporting the development
and maintenance of CNS myelin (Barnett and Linington, 2013). In fact,
dysfunctional astrocytes may negatively affect oligodendrocytes, as ob-
served in a number of diseases in which astrocytic pathology is known
as the direct cause of myelin pathology (Brosnan and Raine, 2013;
Clemente et al., 2013; Lundgaard et al., 2014). Thus, we may also spec-
ulate with the possibility that the up-regulation of pro-inﬂammatory
cytokines in Fxn-deﬁcient astrocytes leads to the demyelination
observed in FA (Corben et al., 2014).
In summary, our results favor the view that Fxn-deﬁcient astrocytes
may contribute to neuropathology in FA through non-cell autonomous
processes including neuroinﬂammation.
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